Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02923934
Recruitment Status : Active, not recruiting
First Posted : October 5, 2016
Last Update Posted : March 3, 2021
Bristol-Myers Squibb
Information provided by (Responsible Party):
Olivia Newton-John Cancer Research Institute

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : April 27, 2020
Estimated Study Completion Date : December 2023